

SINGAPORE
BIOTECH INVEST

21-22 March 2017

Singapore Exchange (SGX)

HONG KONG
BIOTECH INVEST

23-24 March 2017

KPMG Hong Kong

AUSTRALIA-CHINA
BIOTECH INVEST

27-28 March 2017

Shanghai Marriott Hotel City Centre

BARD1 Life Sciences Ltd (ASX:BD1)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. The BARD1 technology platform includes proprietary, proven and specific cancer biomarkers, diagnostic assays and algorithms. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. It is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers including ovarian cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives.

The logo for BARD1 Life Sciences Limited features the word "BARD1" in a large, bold, grey sans-serif font. A stylized, wavy purple and pink ribbon graphic curves underneath the letters "A", "R", and "D". Below "BARD1", the words "LIFE SCIENCES LIMITED" are written in a smaller, grey, all-caps sans-serif font.

BARD1
LIFE SCIENCES LIMITED